Novanta is transforming from a cyclical precision-industrial supplier into a sticky, recurring-revenue medtech compounder, with Riverpoint accelerating the shift but raising integration, leverage, and valuation risk.
Overview
Novanta is a high-quality engineered technology supplier embedded in mission-critical medical, life science, and advanced industrial OEM platforms. Its moat is built on proprietary photonics, vision, precision motion, embedded software, AI capabilities, 1,200+ patents, and deep sole-source design-in relationships. Medical markets now represent the majority of sales, while the Riverpoint acquisition accelerates the shift toward recurring surgical consumables. High switching costs, regulatory re-certification barriers, and long OEM platform lifecycles support durable revenue visibility and pricing power.